The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2023 | The changing role of autoSCT in mantle cell lymphoma: the impact of novel agents
Georg Hess, MD, University Medical Center Mainz, Mainz, Germany, shares some insights into the changing role of autologous stem cell transplantation (autoSCT) in mantle cell lymphoma (MCL), highlighting the toxicity associated with high-dose therapy. Dr Hess further comments on how novel agents are impacting the role of autoSCT in this disease, referencing data from the TRIANGLE trial (NCT02858258). This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, ADC-Therapeutics, AstraZenaeca, BMS, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, Miltenyi, Novartis, Roche
Honoraria: Abbvie, AstraZeneca, Beigene, BMS, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, Roche
Research Funding: Abbvie, Gilead/Kite, Incyte, Janssen, Morphosys, Roche
Patents and Royalties: not applicable
Membership on an entity’s Board of Directors or advisory committees: not applicable
Discussion of off-label drug use: not applicable
Travel grants: Gilead/Kite, Janssen
